OncoMatch/Clinical Trials/NCT06401824
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Is NCT06401824 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab for nsclc stage iv.
Treatment: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab — This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Pathology proven metastatic non-squamous NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy
progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order)
Must have received: platinum-based chemotherapy
progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order)
Must have received: targeted therapy
progression on targeted therapy and platinum-doublet chemotherapy
Cannot have received: TROP2 inhibitor
Previous treatment with TROP2 inhibitor
Cannot have received: angiogenesis inhibitor
Previous treatment with...angiogenesis inhibitor
Cannot have received: anticancer biologic agent (antibody-drug conjugate, immune checkpoint inhibitor)
Exception: within 4 weeks prior to enrolment
prior anticancer biologic agent (ADC, ICI) within 4 weeks prior to enrolment
Cannot have received: chemotherapy
Exception: within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
Cannot have received: targeted small molecule therapy
Exception: within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
Cannot have received: radiation therapy
Exception: within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (without growth factor support); Platelets ≥ 100 x 10^9/L (without growth factor support); Hemoglobin ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth factor support)
Kidney function
Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault or 24-hour urine
Liver function
AST ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases; ALT ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases; Total bilirubin ≤ 1.5 ULN; Serum albumin > 3 g/dL
Adequate organ function including the following laboratory values at the screening visit: ANC ≥ 1.5 x 10^9/L (without growth factor support), Platelets ≥ 100 x 10^9/L (without growth factor support), Hemoglobin (Hb) ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth factor support), AST ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases, ALT ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases, Serum albumin > 3 g/dL, Total bilirubin ≤ 1.5 ULN, Creatinine clearance ≥ 30 mL/min by calculation using Cockcroft-Gault formula or based on 24-hour urine sample assessment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify